Product Program year 2025 Source: CMS Open Payments

Gammaked

Biological Immunology

NDC 76125-900-01

Open in the dashboard

General payments

$366,408

1,958 payments

Research payments

$0

0 payments

Through program year 2025, $366,408 in general payments and $0 in research payments were reported against Gammaked (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Amount Payments
2025 General $87,891 763
2024 General $96,478 861
2023 General $65,574 189
2022 General $17,614 71
2021 General $98,636 64
2020 General $155 7
2019 General $61 3

Breakdown

Who paid General payments · program years 2019–2025
  1. Kedrion Biopharma, Inc. $267,557 1,884 payments
  2. Kedrion Biopharma Inc. $98,852 74 payments
Top recipients General payments · program year 2025
  1. Angela Zhu Ophthalmology · Miami, FL $19,309 22% · 6 payments
  2. Gerami Seitzman Ophthalmology · San Francisco, CA $10,985 12% · 2 payments
  3. Joseph Parker Sleep Medicine · Washington, DC $9,538 11% · 8 payments
  4. Amol Sura Ophthalmology · San Francisco, CA $8,900 10% · 5 payments
  5. Rami Aboumourad Optometrist · Miami, FL $6,435 7% · 4 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Ophthalmology $44,026 50% · 30 practitioners
  2. Sleep Medicine Internal Medicine $9,538 11% · 1 practitioner
  3. Optometrist $6,814 8% · 12 practitioners
  4. Neurology Psychiatry & Neurology $3,330 4% · 101 practitioners
  5. Emergency Medicine $3,204 4% · 52 practitioners

The top 5 of 73 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Florida $28,646 33% · 61 recipients
  2. California $23,819 27% · 42 recipients
  3. District of Columbia $9,538 11% · 1 recipient
  4. New Jersey $4,877 6% · 25 recipients
  5. Minnesota $2,750 3% · 1 recipient

The top 5 of 42 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

17,207

Prescriptions dispensed, refills included

Drug cost

$226,966,042

Paid at the pharmacy, in all

Prescribers

617

With 11 or more claims of it

Medicare Part D drugs matched to GAMMAKED, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Gammaked Immune Globul G/Gly/Iga Avg 46 Same name 617 17,207 $226,966,042

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Sami Khella Neurology PA 278 $2,810,337 None on record
Amanda Witt Physical Medicine and Rehabilitation MS 186 $1,525,632 None on record
Sukanthi Kovvuru Neurology AR 173 $1,805,130 None on record
Riley Snook Neurology IN 172 $1,608,061 $4
Abdul Ahmed Dermatology MA 166 $2,900,356 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to GAMMAKED
Billing code Providers Services Paid by Medicare
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg J1561 206 1,819,367 $69,731,751

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

1,958 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record